MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04762875 |
Recruitment Status :
Terminated
(This study was voluntarily terminated due to a business decision not to proceed and not due to any safety issue)
First Posted : February 21, 2021
Last Update Posted : April 20, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Related Donors Donating PBSC to a Family Member Healthy Donors Acute Myelogenous Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndrome | Biological: MGTA-145 Biological: Plerixafor | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 7 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination With Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies |
Actual Study Start Date : | June 16, 2021 |
Actual Primary Completion Date : | September 14, 2021 |
Actual Study Completion Date : | March 14, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Single dose MGTA-145 plus plerixafor followed by apheresis
MGTA-145 in combination with plerixafor followed by apheresis on one or two consecutive days
|
Biological: MGTA-145
MGTA-145 will be be administered as an IV infusion Biological: Plerixafor 240 µg/kg subcutaneously
Other Name: Mozobil |
- HSC Yield in apheresis product [ Time Frame: Up to 2 days ]To assess the efficacy of MGTA-145 in combination with plerixafor in mobilizing adequate number of hematopoietic stem cells (≥ 2.0 x 10^6 CD34+ cells/kg) in healthy donors in one apheresis setting.
- HSC Yield in apheresis product [ Time Frame: Up to 2 days ]To determine the proportion of donors whose cells can be successfully mobilized and collected with a target CD34+ cell dose of at least 4.0 x 10^6 CD34+ cells/kg actual recipient weight in one apheresis collection
- Adverse events experienced by donors [ Time Frame: Baseline though day 180 ]To ascertain the incidence of adverse events (AEs) before and during apheresis experienced by donors receiving MGTA-145 + plerixafor
- Infusion related toxicities [ Time Frame: Baseline though 72 hours post donation ]To ascertain the severity of adverse events (AEs) before and during apheresis experienced by donors receiving MGTA-145 + plerixafor
- Neutrophil and platelet engraftment [ Time Frame: Day 28, 56, 100, 180, 365 ]To determine the incidence of and kinetics of neutrophil and platelet recovery after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor
- Graft Durability [ Time Frame: Day 28, 56, 100, 180, 365 ]The proportion of participants with primary and secondary graft failure after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor
- Graft-versus host disease (GVHD) [ Time Frame: Day 21, 28, 56, 100, 180, and 365 ]To determine the incidence and severity of acute and chronic graft versus host disease (GVHD) after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor
- Treatment-related mortality [ Time Frame: Day 21, 28, 56, 100, 180, and 365 ]To determine the proportion of treatment-related mortality and disease relapse/progression after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor
- Progression-free survival [ Time Frame: Day 21, 28, 56, 100, 180, and 365 ]To determine the probability of progression-free survival after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor
- Overall survival [ Time Frame: Day 21, 28, 56, 100, 180, and 365 ]To determine the probability of overall survival after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor
- Adverse Events related to Allograft [ Time Frame: Day 0 through 365 ]To characterize the adverse effects experienced by recipients receiving grafts mobilized by MGTA-145 + plerixafor

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Donor Inclusion Criteria:
- Donor medical suitability and eligibility will be determined following Institution or NMDP/Be The Match standards
- Age 18-65 years old at the time of signing informed consent
- 8/8 (HLA- A, B, C, and DRB1) HLA-matched sibling or volunteer unrelated donor
- Fulfill Institution or NMDP/Be The Match criteria to serve as a mobilized blood cell donor
- Serum creatinine < 1.5 x institution upper limit of normal (ULN) or estimated creatinine clearance (CRCL) > 50 mL/min using the Modification of Diet in Renal Disease Study (MDRD) equation or similar method
Recipient Inclusion Criteria:
- At least 18 years old at the time of signing informed consent
- Has an available 8/8 (HLA- A, B, C, and DRB1) HLA-matched sibling or volunteer unrelated donor willing to donate peripheral blood stem cells (PBSC) for transplant
- Fulfill additional individual Transplant Center Criteria for transplant beyond NMDP/Be The Match criteria
-
One of the following diagnoses:
- Acute myelogenous leukemia (AML) in 1st remission or beyond with ≤ 5% marrow blasts and no circulating blasts. Documentation of bone marrow assessment will be accepted within 45 days prior to the date of consent.
- Acute lymphoblastic leukemia (ALL) in 1st remission or beyond with ≤ 5% marrow blasts and no circulating blasts. Documentation of bone marrow assessment will be accepted within 45 days prior to the date of consent.
- Patients with myelodysplasia (MDS) with no circulating blasts and with less than 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with < 5% or 5-10% blasts in MDS). Documentation of bone marrow assessment will be accepted within 45 days prior to the date of consent.
- Cardiac function: Left ventricular ejection fraction at least 45% based on most recent echocardiogram or MUGA results obtained via standard of care
- Estimated creatinine clearance acceptable per local institutional guidelines
- Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin at least 50% and forced expiratory volume in first second (FEV1) predicted at least 50% based on most recent DLCO results obtained via standard of care
- Liver function acceptable per local institutional guidelines
- Karnofsky performance status (KPS) of 70% or greater
- Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score of 4 or less
Exclusion Criteria:
Donor Exclusion Criteria:
- Donor unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing
- Donor already enrolled on another investigational agent study
- Pregnant or breastfeeding females, sexually active female and male donors not willing or able to use adequate contraception, or males who do not agree to refrain from donating sperm, from the time of consent through 3 months after treatment with MGTA-145 + plerixafor
Recipient Exclusion Criteria:
- Subject unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing
- Subject whose donor does not meet the eligibility criteria and is a screen fail
- Subjects with a prior allogeneic transplant
- Subjects with active, uncontrolled infection at the time of the transplant preparative regimen
- Pregnant or breastfeeding females, sexually active female or male subjects not willing or able to use adequate contraception, or males who do not agree to refrain from donating sperm, from the time of consent through 3 months after PBSC infusion
- Subjects with clinical evidence of active Central Nervous System (CNS) tumor involvement as evidenced by documented disease on examination of spinal fluid or MRI within 45 days of start of conditioning
- A condition, which, in the opinion of the clinical investigator, would interfere with the evaluation of primary and secondary endpoints
- Planned treatment with a new investigational agent from the time of transplant through 30 days post-transplant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04762875
United States, California | |
City of Hope National Medical Center | |
Duarte, California, United States, 91010 | |
Stanford Health Care | |
Stanford, California, United States, 94305 | |
United States, Georgia | |
Emory University Hospital | |
Atlanta, Georgia, United States, 30322 | |
United States, Minnesota | |
Mayo Clinic Rochester | |
Rochester, Minnesota, United States, 55902 | |
United States, New York | |
Roswell Park Cancer Institute | |
Buffalo, New York, United States, 14203 | |
United States, Ohio | |
Ohio State Medical Center, James Cancer Center | |
Columbus, Ohio, United States, 43210 | |
United States, Texas | |
M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
United States, Washington | |
Be The Match Collection Center Seattle | |
Seattle, Washington, United States, 98101 |
Study Chair: | Steven Devine, MD | National Marrow Donor Program |
Responsible Party: | Magenta Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT04762875 |
Other Study ID Numbers: |
145-ADS-202 |
First Posted: | February 21, 2021 Key Record Dates |
Last Update Posted: | April 20, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myeloid Leukemia, Myeloid, Acute Myelodysplastic Syndromes Neoplasms by Histologic Type Neoplasms Bone Marrow Diseases Hematologic Diseases Leukemia, Lymphoid |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Plerixafor Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |